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Expression of C-reactive protein by renal cell carcinomas and
unaffected surrounding renal tissue.
Background. Elevation of plasma C-reactive protein (CRP)
is common in patients with renal cell carcinoma (RCC). Re-
nal tubular epithelial cells are capable of synthesizing CRP. Al-
though production of interleukin (IL)-6 has been described in
RCC, CRP expression by carcinoma cells has yet not been in-
vestigated.
Methods. In the present study we analyzed CRP plasma levels
as well as intratumoral CRP and IL-6 expression of RCC from
40 patients who underwent radical nephrectomy by means of
quantitative real-time polymerase chain reaction (PCR) and im-
munohistochemistry. For each tumor, specimens were obtained
from tumor center, tumor margin, and unaffected surrounding
renal tissue.
Results. Preoperative plasma CRP levels correlated signifi-
cantly with tumor stage (P = 0.05) and grade (P < 0.01). CRP
mRNA expression was detected in 26 of 33 (79%), 30 of 36
(83%), and 32 of 36 (89%) samples from tumor center, tu-
mor margin, and unaffected surrounding tissue, respectively.
However, levels of CRP mRNA were significantly higher in tu-
mor tissue compared to adjacent renal tissue (P < 0.01). Clear
cell carcinoma exhibited significantly higher CRP mRNA levels
than papillary carcinoma (P < 0.05). CRP plasma levels corre-
lated significantly with quantitative levels of CRP mRNA within
tumors (P < 0.0001). Immunohistochemically, strong CRP pro-
duction was observed both in tumor cells and in tubular epithe-
lial cells in unaffected tissue, respectively. All kidneys expressed
IL-6 mRNA in the tumor and/or the unaffected tissue, but levels
of intratumoral IL-6 mRNA showed no significant correlation
with CRP plasma levels or local CRP transcription.
Conclusion. In patients with RCC, a tumor-derived origin of
some plasma CRP is likely. Activity of the IL-6/CRP network
in RCC contributes to the accumulating evidence of the acute-
phase reaction as a local inflammatory process.
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C-reactive protein (CRP) is an acute phase reactant,
whose plasma levels increase up to 1000-fold in response
to microbial infection, trauma, infarction, autoimmune,
or malignant diseases. Due to its ability to bind to sev-
eral microbial cell wall and cell membrane components
as well as to nuclear antigens, it plays an essential role in
the clearance of infective or necrotic particles via phago-
cytes. Upon ligand binding, CRP is capable of activat-
ing the classic pathway of complement, but inhibits the
formation of the terminal membrane attack complex.
Considering the numerous and sometimes opposing ac-
tivities of CRP it is regarded as a proinflammatory as well
as anti-inflammatory molecule active in innate immunity
and tissue homeostasis (for review, see [1]). The origin
of plasma CRP was initially described as being restricted
to the liver [2]. However, recent data have demonstrated
a local expression of this prototypic acute phase protein
in the kidney, the respiratory tract, the thymus, adipose
tissue, in smooth muscle cells of normal and diseased ves-
sels, and in neuronal cells, rejecting the liver as the only
site of CRP production [3–9].
An increase in plasma CRP without apparent inflam-
matory disease or without any other underlying condition
known to be associated with minor CRP elevation (such
as atherosclerosis, infarction, obesity) may suggest clini-
cally unapparent malignancy, as nearly every malignant
disease induces perturbations of plasma levels of acute
phase proteins. Indeed, CRP elevations have been found
in the course of all types of carcinomas as well as lym-
phomas, sarcomas, and cerebral tumors [10, 11]. In renal
cell carcinoma (RCC), the rise in plasma CRP correlates
with tumor burden and metastases. Therefore, CRP has
been identified as one of the most significant predictor of
patients’ overall survival [12–14]. The origin of “tumor
CRP” is unexplained or, at most, linked to interleukin
(IL)-6 secretion by the tumor stimulating CRP synthe-
sis in hepatocytes [15, 16]. However, CRP expression by
malignant cells itself has not been investigated in detail,
explaining tumor-associated CRP elevations more easily.
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Table 1. Preoperative and perioperative characteristics of 40 renal cell carcinoma (RCC) patients
Age Tumor White blood Plasma Urine CRP/MPO Urine
Patient Gender years Histology size cm Stage Grade cell count/nL CRP mg/L lg/L bacteriology
1 M 64 Clear cell 6.9 T2 G2 6.2 40 0 Negative
2 M 69 Clear cell 10.3 T3 G1 10.3 10 0 Negative
3 M 60 Clear cell 2.5 T1 G2 7.7 18 0 Negative
5 M 65 Clear cell 6.0 T2 G2 8.1 7 0 ND
6 F 86 Clear cell 4.1 T3 G2 11.8 15 0 Negative
7 M 41 Clear cell 7.5 T2 G2 12.6 12 0 Negative
8 M 89 Papillary 1.0 T1 G2 5.9 0 ND ND
9 F 67 Papillary 2.5 T1 G3 7.9 32 0 ND
10 M 60 Clear cell 6.0 T1 G1 8.2 4 ND ND
11 M 55 Clear cell 11.0 T3 G2 6.9 0 ND Negative
12 F 70 Clear cell 6.0 T3 G3 9.8 94 0 Negative
13 M 62 Papillary 7.5 T3 G2 6.0 13 ND Negative
14 M 80 Clear cell 4.5 T1 G2 7.3 71 ND ND
15 F 46 Clear cell 5.6 T1 G3 6.7 0 ND ND
16 M 60 Clear cell 2.8 T1 G2 4.8 0 ND Negative
17 M 81 Clear cell 12.0 T3 G3 8.0 121 ND ND
18 F 68 Clear cell 6.0 T2 G2 7.4 0 ND ND
19 M 64 Clear cell 4.5 T1 G2 8.4 13 ND ND
20 M 50 Clear cell 3.0 T1 G2 7.0 2 ND Negative
21 M 71 Clear cell 6.0 T1 G3 8.1 28 ND ND
22 F 56 Clear cell 2.7 T1 G2 9.1 0 ND ND
23 M 71 Papillary 4.5 T1 G2 8.1 0 ND ND
24 M 61 Papillary 5.3 T3 G2 8.6 103 ND ND
25 M 68 Papillary 5.4 T1 G2 9.5 7 ND ND
26 F 61 Clear cell 5.5 T1 G2 7.5 3 ND Negative
27 F 71 Clear cell 13.0 T2 G2 7.9 14 ND ND
29 M 59 Papillary 2.6 T1 G2 6.1 0 ND Negative
30 F 54 Papillary 1.8 T1 G2 6.0 0 ND Negative
31 F 62 Clear cell 8.0 T2 G2 9.2 60 ND Negative
32 F 61 Clear cell 2.6 T1 G2 7.2 10 ND Negative
33 M 46 Clear cell 3.6 T1 G2 12.6 0 ND Negative
34 M 68 Clear cell 6.5 T3 G2 11.4 1 ND Negative
35 M 63 Clear cell 12.5 T3 G2 6.5 9 ND ND
36 M 73 Clear cell 13.0 T3 G1 5.1 3 ND Negative
38 F 77 Papillary 4.0 T1 G2 7.6 8 ND Negative
39 F 38 Spindle cell 22.0 T3 G2 6.0 0 ND ND
40 M 76 Clear cell 12.0 T3 G3 6.4 54 ND ND
41 M 40 Clear cell 7.4 T3 G3 6.5 7 ND neg.
46 M 63 Clear cell 9.0 T3 G2 7.9 13 ND neg.
47 M 48 Clear cell 9.0 T3 G2 6.2 9 ND neg.
Abbreviations are: M, male; F, female; ND, not determined.
Therefore, we investigated production of CRP by RCC
cell lines and in tumor-bearing kidneys and compared the
results to preoperative CRP plasma levels as well as to
tumor stage, grade, and IL-6 mRNA expression of the
tumors.
METHODS
Patients’ characteristics and tissue collection
Initially, 47 consecutive patients with unilateral renal
masses suspicious of RCC by means of computed tomog-
raphy or magnetic resonance imaging were prospectively
enrolled into this study. Seven patients were excluded
from further investigations, since the histologic exami-
nation revealed tumors different from RCC (two benign
tumors and five chronic infections). All patients under-
going radical nephrectomy gave their informed consent
for scientific investigations of the removed kidneys. This
study was approved by our local ethic committee. Clini-
cal and histologic data for the remaining 40 patients are
given in Table 1. To exclude urinary tract infections prior
to nephrectomy, 22 patients gave urine preoperatively for
bacteriology. None of these patients had a significant bac-
teriuria (see Table 1 for details). Moreover, white blood
cell counts were measured preoperatively in all patients.
Leukocytes ranged between 4.8 and 12.6 per nanoliter,
median 7.7/nL. Those with counts above 10.0/nL neither
had fever nor CRP levels different from the rest of the
group. In addition, CRP and myeloperoxidase (MPO)
concentrations were determined in preoperative urine
samples of eight patients by means of a highly sensitive
immunoluminometric assay [17]. This assay proved to be
helpful in the diagnosis of urinary tract infections of kid-
ney transplant recipients. As none of these early patients
tested positive for urinary CRP or MPO, we did not fol-
low the remaining patients.
For each tumor, specimens were obtained from the tu-
mor center (which was necrotic in many cases), the vital
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tumor margin and the unaffected surrounding renal tis-
sue immediately (less than 3 minutes) after nephrectomy.
For immunohistochemistry, a piece of about 0.125 cm3
was cut from each of the three sites, covered with tissue-
freezing medium (Jung, Nussloch, Germany) and stored
at −80◦C. For transcriptional analysis, tissue specimens
from each region were obtained with an 18 gauge Tru-
cut biopsy needle. Samples were immediately transferred
into a guanidine isothiocyanate–containing lysis buffer
substituted with 2-mercaptoethanol (RLT buffer) (Qia-
gen, Hilden, Germany) and stored at −80◦C until further
use. The nephrectomy specimen was then fixed in 4.5%
buffered formalin and prepared for histopathologic ex-
amination. Classification of tumor stage was done accord-
ing to the Union International Contre le Cancer (UICC)
classification [18], and staging according to the classifica-
tion of Thoenes, Sto¨rkel, and Rumpelt [19]. All cases were
reviewed for correct stage and grade by a local pathol-
ogist, who was blinded to the CRP data. Due to mostly
negative or unknown data, we did not include lymph node
status (N) and status of metastases (M) into our analysis.
RNA extraction and cDNA synthesis
Samples for RNA extraction were thawed in batches
of 12 and processed immediately thereafter. Tissue in
lysis buffer was further disrupted by thorough vortex-
ing for about 1 minute. Afterward, lysed tissue was ho-
mogenized by spin columns (homogenizer) (Qiagen) and
flow-through was loaded onto the silica membranes of
RNeasy mini-columns (Qiagen). Further extraction fol-
lowed the recommendations of the manufacturer. Total
RNA was eluted in 30 mL of RE buffer (Qiagen). Twenty
microliters of RNA were then reverse transcribed using
random primer (Gibco, Karlsruhe, Germany) and Super-
script II Reverse Transcriptase (Gibco). The resulting
cDNA was stored at −80◦C and thawed first for CRP
and then for IL-6 mRNA determination.
Quantitative real-time polymerase chain reaction (PCR)
Quantitative real-time PCR (TaqManTM PCR; Ap-
plied Biosystems, Darmstadt, Germany) for CRP mRNA
detection was performed with the ABI Prism 7700 Se-
quence Detection System (Applied Biosystems) and ex-
actly followed our recently published protocol [3]. In
brief, CRP mRNA was detected in a multiplex real-time
PCR reaction amplifying CRP and hypoxanthine phos-
phoribosyltransferase (HPRT) cDNA within the same
tube. HPRT coamplification was used for normaliza-
tion of the CRP amplification signal avoiding tube-to-
tube variations and pipetting errors. All determinations
were done in duplicate taking the mean of both reac-
tions for quantitative analysis. Quantification of relative
CRP mRNA levels was carried out by calibrating against
a cDNA from maximally stimulated Hep3B cells, which
was amplified in each experiment in duplicate as well.
Results are always given as multiplicities of this calibra-
tor. The heptoma-derived cell line Hep3B exhibits an
inducible CRP transcription and has been studied exten-
sively regarding its CRP expression [3, 20]. After stimu-
lation, it is a reliable source of detectable CRP mRNA.
Since, to our best knowledge, there is no renal epithe-
lial cell line with a comparable CRP expression, Hep3B
cells were stimulated with a conditioned medium at a
density of 1 × 106/mL in 10 mL culture flasks for 48
hours prior to RNA extraction for preparation of the cal-
ibrator cDNA. Conditioned medium had already been
shown previously to yield the highest CRP induction in
Hep3B cells after 48 hours [3]. It was made by stimulating
peripheral blood mononuclear cells of a healthy donor
with lipopolysaccharide (10 ng/mL) over night, using
the filtered culture supernatant as conditioned medium.
The cDNA from conditioned medium–stimulated Hep3B
cells was aliquoted into 10 lL specimens, which were
thawed only twice to avoid significant degradation due
to repeated freeze-thaw cycles. Only one batch of Hep3B
cDNA was used throughout the whole study. IL-6 mRNA
was detected by quantitative real-time PCR as well, us-
ing predeveloped primer/probes purchased from Applied
Biosystems. Forty cycles of amplification were performed
at 60◦C for 1 minute and at 95◦C for 15 seconds. Calibra-
tion was carried out with the same calibration sample
used for CRP mRNA quantification. Results were again
calculated as multiplicities of this calibrator.
Immunohistochemistry
Staining for CRP protein using the APAAP technol-
ogy followed the protocol described before in detail [3].
Immunohistochemistry was done on fresh-frozen, 4 lm
thick sections of the respective tumor/kidney areas or on
cell monolayers of the RCC cell line CaKi, which were
grown on LabTecTM chamber slides (Nunc, Wiesbaden,
Germany). The monoclonal anti-CRP antibody (Sigma
Aldrich, Munich, Germany) had already been shown to
stain specifically native CRP by preincubation with native
recombinant CRP (Calbiochem, San Diego, CA, USA)
and subsequent loss of staining as well as by isotype con-
trol staining used in each experiment [3].
Statistical analysis
Comparison of CRP mRNA levels between different
regions of nephrectomized kidneys was done by nonpara-
metric Wilcoxon test (paired samples). Bivariate corre-
lation analyses were performed by Pearson test. Results
were confirmed by partial correlation correcting for age,
gender, and histology of the tumor. CRP plasma and ex-
pression levels at increasing tumor stages and grades were
compared with the nonparametric Kruskal-Wallis test.
Values are given as mean ± SD.























































Fig. 1. Preoperative C-reactive protein (CRP) plasma levels of 40 re-
nal cell carcinoma (RCC) patients in correlation to tumor stage and
grade. (A) Tumor stage according to the Union International Contre le
Cancer (UICC) classification from 1997 [18]. ∗v 2 = 5.68; P = 0.059 by
Kruskal-Wallis test. (B) Tumor grading according to the classification
by Thoenes, Sto¨rkel, and Rumpelt from 1986 [19]. ∗ v 2 = 6.52; P < 0.05
by Kruskal-Wallis test.
RESULTS
Plasma CRP: Dependence on tumor stage and grade
We first analyzed preoperative plasma CRP levels
in all study patients with regard to tumor stage and
grade. Analysis by Kruskal-Wallis test revealed that CRP
plasma levels correlated tendentiously (v 2 = 5.68) (P =
0.059) with tumor stage and significantly (v 2 = 6.52) (P <
0.05) with grade, which is depicted in Figure 1. Partial cor-
relation, corrected for age, gender, and tumor histology,
confirmed a significant association between CRP values
and tumor stage (r = 0.3312) (P < 0.05) as well as tumor
grade (r = 0.4327) (P < 0.01).
CRP expression: Immunohistochemistry
and mRNA quantification
To analyze a possible expression of CRP by RCC,
we first studied the RCC cell line CaKi (kind gift from
Dr. C. Frohn, Institute of Immunology and Transfusion
Medicine, University of Luebeck, Luebeck, Germany)
by means of quantitative real-time PCR. Native CaKi
cells gave a clear amplification signal for detectable CRP
mRNA, which was about five log ranks below the maxi-
mally stimulated Hep3B control cells (data not shown).
Moreover, unstimulated CaKi cells showed a homoge-
nous cytoplasmic CRP staining by monoclonal anti-CRP
and APAAP technology (Fig. 2A and B).
In tumor specimens, we observed a perinuclear stain-
ing pattern for CRP by means of immunofluorescence
staining that was either localized to single tumor cells
of necrotic areas or to some tumor cells of the viable
margins (Fig. 2C and D). Interestingly, CRP production
sometimes appeared as a very bright homogenous stain-
ing pattern in clusters of tumor cells of tumor margins
(Fig. 2E). In the surrounding renal tissue of RCC, CRP
production was confined to the tubular epithelium, where
staining followed the same pattern as observed for tu-
mor cells: perinuclear staining of some epithelial cells,
but bright cytoplasmic coloring in a few tubules as well
(Fig. 2F). Due to the relatively poor quality of fresh-
frozen tissue specimens, we were not able to define partic-
ular tubular segments responsible for these two different
staining patterns.
We then investigated CRP mRNA expression in cDNA
preparations from tumor-derived and surrounding tis-
sues. Twenty six of 33 specimens (79%) derived from the
tumor center, 30 of 36 (83%) from the tumor margin,
but also 32 of 36 (89%) samples from adjacent healthy
tissue were positive for CRP mRNA. Missing sample
numbers to 40 are due to low RNA yields causing weak
signals for the internal control HPRT that did not allow
for definite conclusions about CRP expression. Ct values
of the HPRT amplifications plots, which usually were in
the range between 20 and 25, of greater than 30 served
for exclusion from further analysis. Figure 3A gives rep-
resentative examples of CRP and HPRT amplification
plots for the three different kidney regions (pat. no. 41,
see Table 1). In those samples, which could have been ap-
propriately analyzed, a remarkably higher CRP mRNA
expression was observed in tumor-derived tissues com-
pared to the unaffected kidney poles. This difference was
statistically significant between vital tumor margins and
adjacent kidneys (Wilcoxon test, P < 0.01) (Fig. 3B). Nev-
ertheless, the three different kidney regions correlated to
each other in their degree of CRP mRNA expression with
r = 0.964 for tumor center vs. margin, r = 0.822 for tumor
center vs. adjacent kidney, and r = 0.676 for tumor mar-
gin vs. adjacent kidney (all P < 0.001). Furthermore, CRP
mRNA expression levels increased significantly with tu-
mor grade (v 2 = 12.74) (P < 0.01) for tumor centers;
(v 2 = 13.64) (P < 0.01) for tumor margins; and (v 2 =
6.73) (P < 0.05) for adjacent kidney tissue, as given
in Figure 3C, but not with regard to tumor stage




Fig. 2. Frozen sections of renal cell carcinoma (RCC) and surrounding renal tissue as well as Caki cells grown on chamber cultures slides immunos-
tained for C-reactive protein (CRP) using APAAP methodology and naphthole/neofuchsin. Immunoreactivity was examined by monoclonal
anti-CRP antibody (Sigma Chemical Co.). (A) Cytoplasmic, homogenous immunoreactivity for CRP in Caki cells (original magnification ×400).
(B) Caki cells stained with an irrelevant isotype control antibody (original magnification ×400). (C) Perinuclear staining for CRP in some tumor
cells of the viable margin besides tumor cell clusters with intense homogenous coloring (pattern 12, original magnification ×200). (D) Isotype
control staining of the tumor margin (pattern 12, original magnification ×200). (E) Detailed view on CRP immunoreactivity in RCC tumor cells
with perinuclear staining (←) or bright homogenous (→) coloring (pattern 12, original magnification ×400). (F) CRP immunoreactivity in adjacent
renal tissue with perinuclear staining (←) of some tubular epithelial cells and a few more homogenously (→) stained tubules. (→) depicts interstitial























































































Fig. 3. Detection of C-reactive protein (CRP) mRNA by quantitative multiplex real-time TaqManTM polymerase chain reaction (PCR). (A)
Amplification plots for CRP (left panel) and for hypoxanthine phosphoribosyltransferase (HPRT) (right panel) mRNA detection in tumor center
(C1 and C2), tumor margin (C3 and C4), and adjacent tissue (C5 and C6) of pattern 41. Y axis shows the normalized and baseline-corrected reporter
signal Rn (VIC dye for CRP, FAM dye for HPRT detection), x axis shows the cycle numbers. Note the significantly lower Rn values for HPRT,
which are due to limited primer/probe concentrations to avoid competition with concurring CRP mRNA amplification. (B) Mean CRP mRNA
levels for all 40 renal cell carcinoma (RCC) in tumor centers, margins, and adjacent renal tissues. ∗P < 0.01 by Wilcoxon test. (C) Mean CRP mRNA
levels of the three different tumor regions with regard to tumor grading. Note the particularly strong positive correlation between tumor grade and
CRP mRNA levels. ∗∗P < 0.01 for tumor center as well as for tumor margin; ∗P < 0.05 for adjacent kidney.
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Fig. 4. Subtype-dependent C-reactive protein (CRP) mRNA expression of renal cell carcinoma (RCC) as well as correlation between intratumoral
CRP mRNA expression and preoperative CRP plasma levels. (A) Analysis of CRP mRNA levels in the two main different RCC subtypes, clear cell
and papillary, revealed significantly elevated levels in clear cell compared to papillary carcinoma. ∗P < 0.05. n.s. is not significant. (B) CRP mRNA
was quantified as described in detail in [3]. CRP mRNA of tumor centers and tumor margins are plotted against respective CRP plasma levels. The
given correlations were highly significant, even when corrected for age, gender, and histology of the tumors.
(Kruskal-Wallis test, data not shown). Analysis of
subtype-dependent CRP expression revealed signifi-
cantly higher CRP mRNA levels in clear cell than in pap-
illary carcinomas (Fig. 4A).
Correlation of plasma CRP with intratumor CRP
and IL-6 mRNA expression
To correlate plasma CRP to intratumor CRP produc-
tion, quantitative CRP mRNA data of the three differ-
ent regions were compared to preoperative CRP plasma
levels. This analysis revealed a highly significant positive
correlation between the magnitude of CRP mRNA ex-
pression in all three kidney regions and CRP plasma lev-
els, even when corrected for patients’ age, gender, and
histology of the tumor (shown in Fig. 4B for tumor cen-
ters and margins).
Finally, we investigated IL-6 expression of all tissue
samples. Transcription of IL-6 mRNA was observed in
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all tumors that also showed CRP synthesis by malignant
cells and/or surrounding healthy tissue. Although the
IL-6 expression levels in the different kidney regions were
comparable to CRP mRNA levels, we did not find a sig-
nificant correlation between IL-6 and CRP mRNA ex-
pression or between IL-6 expression and CRP plasma
levels (data not shown).
DISCUSSION
In 2004, a total of 35,710 new cases of kidney can-
cer and renal pelvis cancer were expected in the United
States [21]. At the time of diagnosis 54% of patients
have organ-confined tumors, 21% locally advanced tu-
mors, and 25% have metastatic tumors. Corresponding
5-year survival rates are 89%, 61%, and 9%, respectively.
Standard therapy of organ-confined or locally advanced
kidney cancer is operative removal of the tumor (total
or partial nephrectomy, open operative, or laparoscopic
approach). However, depending on tumor stage up to
50% of patients will develop metastases [22]. Standard
therapy of metastatic kidney cancer includes systemic ad-
ministration of cytokines like interferon (INF)-a and IL-2
either alone or in combination (also with chemotherapeu-
tic agents like 5-fluorouracil or vinblastine) [23]. Unfortu-
nately, median survival of these patients is 12 to 15 months
and less than 10% survive for more than 5 years [24].
Rises in plasma CRP have repeatedly been proven to
indicate tumor progression [12–14]. This study aimed to
investigate a local origin of elevated plasma CRP in pa-
tients with RCC. We describe, for the first time, an au-
tochthonous production of the acute phase protein CRP
by RCC cells as well as by nontumorous renal tissue in
vitro and in vivo. With respect to the specificity of CRP
production in cancers, there is one study which described
the immunohistochemical production of CRP by squa-
mous cell carcinoma of the esophagus, however, not con-
firming this observation by transcriptional analysis of the
CRP gene within the tumors [24]. Nevertheless, the au-
thors concluded that intratumoral CRP expression along
with high plasma CRP levels identified patients with unfa-
vorable outcomes. We have started to extend our work on
carcinomas of the prostate, the colon, and head, and neck
squamous cell cancers, providing evidence for CRP gene
transcription also in these entities (unpublished data).
Another group showed an inducible expression of CRP
by the human lung epithelial carcinoma cell line A549
[25], which again suggests that CRP expression by malig-
nant cells is not restricted to RCC.
Like other studies, we observed remarkably high CRP
plasma levels in some RCC patients, who nonetheless
lacked clinical signs of infections (fever, chills, myal-
gia, coughing, or symptoms of urinary tract infection)
and were in a satisfactory health state enabling radical
nephrectomy. Thus, elevated CRP levels had to be at-
tributed to the diagnosis of RCC. The positive correla-
tion between the tumor stage (T1−3) and CRP plasma
levels is an interesting novel observation, which clearly
demonstrates the relationship between tumor size and
CRP plasma levels and therefore argues for a local ori-
gin of “tumor CRP.” However, the mass of the tumor
might not be the only factor influencing CRP plasma lev-
els in RCC patients, and a contribution of liver-derived
CRP to elevated plasma levels is likely, too, regarding
considerably increased serum levels of IL-6 in these pa-
tients [15]. The extent of inflammation (either cellular
infiltrates or autochthonous activation of proinflamma-
tory signaling molecules) in the tumor may also influence
CRP production of tumor cells. In fact, tumors with in-
flammatory reactions have been identified as particularly
aggressive with a poor prognosis [26, 27]. CRP expression
is induced by IL-6 and other factors, such as IL-1, comple-
ment components, and steroid hormones. The principally
active transcription factors in the regulation of CRP ex-
pression in the liver bind to C/enhancer binding protein
(EBP) and signal transducers and activators of transcrip-
tion 3 (STAT3) response elements upstream of the pro-
moter [28]. Furthermore, nuclear factor-kappaB (NF-jB)
has recently been shown to participate in hepatic CRP in-
duction and to act synergistically with C/EBP and STAT3
[29]. There is now compelling evidence that especially
high-grade RCC display increased C/EBP-b as well as
NF-jB activation causing an inflammatory, more aggres-
sive phenotype [26, 27]. Activation of principal CRP in-
ducers and enhancer proteins, therefore, may account for
the significantly increased CRP expression in high-grade
RCC with increased CRP plasma levels observed in this
study. Increased activation of proinflammatory transcrip-
tion factors causing CRP expression can be explained by
autocrine secretion of IL-6 from tumor cells that may
act via its receptor on RCC [30–32]. Although we de-
tected IL-6 gene transcription in all samples positive for
CRP mRNA, we were not able to correlate these find-
ings to intratumoral CRP expression or to plasma CRP.
IL-6 expression levels showed an extremely wide range
over seven orders of magnitude. This strong diversity in
IL-6 expression might result from p53 mutations in RCC,
which have recently been shown to dramatically influence
autocrine IL-6 production of RCC [32]. We also have to
keep in mind that IL-6 is necessary, yet not sufficient for
CRP induction, suggesting that other local factors within
tumors regulate CRP expression as well. The observa-
tion that clear cell carcinoma express significantly more
CRP than do papillary carcinoma is in line with a worse
outcome for RCC patients with elevated CRP plasma
levels and better survival rates for patients with papillary
RCC [33]. Therefore, it is tempting to speculate that in-
tratumoral expression of CRP indeed is an independent
prognostic risk factor in RCC.
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CONCLUSION
Our experiments suggest a local origin of “tumor
CRP” in patients with RCC. Furthermore, the data justify
monitoring of CRP levels in RCC patients after radical
nephrectomy or other therapeutic interventions. Finally,
these results contribute to the accumulating evidence that
the acute phase reaction, or at least parts of it, does not
always represent a systemic response pathway, but also
takes place in local environments, such as inflamed [3, 34]
or malignant kidneys.
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